title: Biochemical and pharmacological characteristics of a newly synthesized H+/K+-ATPase inhibitor, YJA20379-8, 3-butyryl-4-[R-1-methylbenzylamino]-8-ethoxy-1,7-naphthyridine, in pigs and rats.
abstract: We have investigated the effect of the newly synthesized proton-pump inhibitor YJA20379-8, 3-butyryl-4-[R-1-methylbenzylamino]-8-ethoxy-1,7-naphthyridine, on gastric mucosal proton pump (H+/K+-ATPase) activity, gastric acid secretion and gastric lesions in experimental animals. In lyophilized pig gastric microsomes, YJA20379-8 was shown to inhibit H+/K+-ATPase activity; the inhibitory effect was not affected by pH, the IC50 (dose resulting in 50% inhibition) being 28.0 microM and 30.0 microM at pH 6.4 and pH 7.4, respectively. The effect was fully reversed by dilution and subsequent washing of the incubation mixtures of H+/K+-ATPase and YJA20379-8, suggesting the reversible nature of the enzyme inhibition. In pylorus-ligated rats, YJA20379-8 administered by different routes (intraduodenal, subcutaneous, intravenous or oral) resulted in dose-dependent suppression of basal gastric acid secretion. The duration of antisecretory action of 30 mg kg(-1) YJA20379-8 given intraduodenally was very brief (less than 7 h). Pretreatment with YJA20379-8 also dose-dependently prevented gastric lesions induced by absolute ethanol and water-immersion stress in rats. These results suggest that YJA20379-8 might exert its antiulcer activity partly by reversible suppression of acid secretion and partly by protecting the gastric mucosa against ulcerative stimuli.
authors.affiliation: Pharmacology and Toxicology Laboratory, Research and Development Centre, Yung-Jin Pharmaceutical Co. Ltd, Hwasung-Kun, Kyunggi-Do, Korea.
authors.forename: S K
authors.initials: SK
authors.lastname: Sohn
authors.forename: M S
authors.initials: MS
authors.lastname: Chang
authors.forename: W S
authors.initials: WS
authors.lastname: Choi
authors.forename: Y K
authors.initials: YK
authors.lastname: Chung
authors.forename: K B
authors.initials: KB
authors.lastname: Kim
authors.forename: T W
authors.initials: TW
authors.lastname: Woo
authors.forename: S B
authors.initials: SB
authors.lastname: Lee
authors.forename: C J
authors.initials: CJ
authors.lastname: Park
mesh_terms: D000818:Animals; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D000431:Ethanol / Q000633:toxicity; D005744:Gastric Acid / Q000378:metabolism; D005753:Gastric Mucosa / Q000187:drug effects* / Q000201:enzymology* / Q000378:metabolism / Q000473:pathology; D007101:Immersion; D066298:In Vitro Techniques; D008297:Male; D008861:Microsomes / Q000187:drug effects / Q000201:enzymology; D009287:Naphthyridines / Q000494:pharmacology*; D009853:Omeprazole / Q000494:pharmacology; D010437:Peptic Ulcer / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D054328:Proton Pump Inhibitors; D051381:Rats; D017207:Rats, Sprague-Dawley; D013312:Stress, Physiological / Q000150:complications
chemical_list: C114511:3-butyryl-4-(5R-methylbenzylamino)-8-ethoxy-1,7-naphthyridine; D004791:Enzyme Inhibitors; D009287:Naphthyridines; D054328:Proton Pump Inhibitors; D000431:Ethanol; D009853:Omeprazole